Vascular Headache: Evaluation and Treatment
For vascular-type headaches, start with NSAIDs (ibuprofen 400mg or naproxen) or acetaminophen (1000mg), and if inadequate response, add a triptan to the NSAID or acetaminophen for acute treatment. 1
Acute Treatment Algorithm
First-Line Therapy
- Begin with an NSAID (ibuprofen, naproxen, diclofenac, or aspirin) at adequate dosing, or acetaminophen 1000mg if NSAIDs are contraindicated 2, 1
- Ensure proper dosing before declaring treatment failure—many patients use subtherapeutic doses
Second-Line: Combination Therapy
- Add a triptan to your NSAID or acetaminophen if monotherapy fails 1
- This combination approach is superior to either agent alone
- Available triptans include: sumatriptan, rizatriptan, eletriptan, almotriptan, naratriptan, frovatriptan, or zolmitriptan
- Choose specific triptan based on route preference (oral, nasal, subcutaneous) and cost
- Critical caveat: Avoid triptans in patients with cardiovascular disease due to vasoconstrictive properties 3
Third-Line Options (When Combination Therapy Fails)
- CGRP antagonists (gepants): rimegepant, ubrogepant, or zavegepant 1
- Eliminate headache in ~20% at 2 hours
- Adverse effects: nausea and dry mouth in 1-4% of patients
- Safe in cardiovascular disease patients
- Lasmiditan (5-HT1F agonist): Reserve for patients who fail all above options 1, 3
- Safe in cardiovascular risk factors
- Use as last resort before considering preventive therapy
What NOT to Use
- Never use opioids or butalbital for acute episodic migraine 1
- These worsen outcomes and increase risk of medication overuse headache
Preventive Therapy Indications
Consider preventive medications when:
- Episodic migraines occur frequently (typically ≥4 days/month)
- Acute treatment provides inadequate response
- Patient develops medication overuse pattern
Preventive Options
- First-line: Topiramate, valproate, angiotensin-receptor blockers, lisinopril, or memantine 2
- CGRP monoclonal antibodies: Newer option with good efficacy (reduce migraine by 1-3 days/month) 2, 3
- Atogepant: Oral CGRP preventive option 2
- OnabotulinumtoxinA: Only for chronic migraine (≥15 headache days/month), NOT episodic migraine 2
- Avoid gabapentin: Not recommended for episodic migraine prevention 2
Critical Red Flags Requiring Urgent Evaluation
Look for these specific features suggesting secondary vascular pathology rather than primary headache:
- Thunderclap onset (subarachnoid hemorrhage) 4
- Age ≥50 years with new-onset headache (temporal arteritis, mass lesion) 3
- Neurologic deficits on examination 3
- Cancer or immunosuppression history 3
- Provocation by Valsalva, cough, or postural changes (increased intracranial pressure) 3
- Headache unresponsive to appropriate treatment over time (consider vascular malformation, aneurysm) 5
When these features are present, neuroimaging with CT angiography or MR angiography is essential to exclude vascular causes like aneurysm, vasculitis, or arterial dissection 6, 5.
Special Considerations
Medication Overuse Headache
- Occurs with ≥15 days/month of simple analgesics or ≥10 days/month of triptans for ≥3 months 1
- Monitor frequency of acute medication use closely
- Transition to preventive therapy if approaching these thresholds
Severe Nausea/Vomiting
Pregnancy and Lactation
- Discuss adverse effects of all pharmacologic treatments 1
- Most migraine medications have limited safety data in pregnancy
- Acetaminophen generally considered safest option
Treatment Timing
Counsel patients to treat at headache onset, not after it becomes severe—early treatment with combination therapy improves efficacy 1.